ArticleAnalytical chemistry2025
Anion Exchange Chromatography to Determine mRNA Encapsulation in Lipid Nanoparticles.
Article in Analytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From nucleotides to intact transcripts through oligonucleotides: Integrated chromatographic strategies for therapeutic mRNA characterization.Analytical and bioanalytical chemistry · 2026Review
- Next-Generation Nanocarrier Platforms for RNA Vaccines: Advances in Formulation, Stability Engineering, and Translational Manufacturing Challenges.Pharmaceutics · 2026Review
- Analytical Characterization and Stability Assessment of RNA-Based Vaccines.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Encapsulation efficiency (EE) of mRNA-based therapeutics and vaccines is defined as the percentage of total mRNA that is efficiently protected by the delivery vehicle from nuclease degradation. As a critical quality attribute, EE must be assessed to ensure that sufficient mRNA evades enzymatic degradation and traverses biological barriers to reach the cellular machinery for translation, without triggering unwanted immune responses caused by free mRNA. In this study, we developed a strategy based on anion exchange chromatography (AEX) to separate lipid nanoparticles (LNPs) and free mRNA based on their charge differences. Carryover issues were mitigated by using a washing step with surfactant, high pH, and high salt concentration. EE was determined by analyzing undiluted samples for free mRNA and measuring total mRNA after LNP disruption using surfactants. The method was successfully applied to the analysis of 30 different mRNA-LNP samples to determine EE. The results were compared to those obtained with the RiboGreen assay, one of the reference methods to assess EE. Our results revealed significant discrepancies between the two techniques that could be explained by the structural information obtained under AEX conditions. Indeed, while the RiboGreen assay provides information on the quantification of mRNA accessible to the fluorescent dye, AEX allows relative quantification of mRNA dissociated from LNPs and information on the presence of surface-localized mRNA as well as transmembrane mRNA. These findings establish AEX as a reliable EE assay, providing information on mRNA distribution within LNPs and advancing the fundamental understanding of LNP structure-function relationships. Based on these features, it offers critical guidance for the rational design of next-generation mRNA therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.